“A LIPOSOMAL CO-DELIVERY SYSTEM FOR DOXORUBICIN AND AN ANTI-PD-L1 NANOBODY SYNERGIZES CHEMO-IMMUNOTHERAPY IN A MURINE COLON CARCINOMA MODEL” (2025) Journal of Medical & Health Sciences Review, 2(4). doi:10.65035/3qvcqd73.